Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Calcium Channel Blocker Industry?

The market for calcium channel blockers has displayed robust growth in the past few years. Currently valued at $15.56 billion in 2024, it is projected that it will expand to $16.46 billion in 2025, marking a compound annual growth rate (CAGR) of 5.8%. The push factor for this acceleration during the historical period includes a higher prevalence of cardiovascular ailments, an aging demographic, innovations in medical investigation, lifestyle modifications, and enhanced awareness.

The market size for calcium channel blockers is anticipated to experience robust expansion in the forthcoming years, escalating to “$21.59 billion in 2029 with a compound annual growth rate (CAGR) of 7.0%. This projected growth can be credited to the increasing global incidence of cardiovascular disorders, the prevalence of personalized medicine, enhanced healthcare accessibility, widened indications, regulatory sanctioning, and market development. The trends that will be prominent during this forecast period encompass market expansion, technological progress, regulatory environment, competitive scrutiny, patient inclinations, and awareness.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9428&type=smp

What Forces Are Driving The Growth Of The Calcium Channel Blocker Industry?

The calcium channel blocker market’s expansion is projected to be propelled by the growing incidence of cardiovascular ailments. Cardiovascular disease, which impacts the heart or blood vessels, is mitigated by calcium channel blockers (CCBs), reducing the likelihood of heart failure and stroke. Thus, the escalating rates of cardiovascular diseases will spur the demand for calcium channel blockers. For example, as per a report by the American College of Cardiology in August 2022, the four major cardiovascular risk factors are projected to surge in the United States between 2025 and 2060. Diabetes is predicted to see the most significant percentage increase, rising by 39.3% to impact 55 million people, followed by dyslipidemia affecting 126 million (an increase of 27.6%), hypertension impacting 162 million (up by 25.1%), and obesity affecting 126 million (an increment of 18.3%). Moreover, the study noted the most significant estimated rise in rates of cardiovascular disease, with stroke increasing by 33.8% to 15 million and heart failure by 33.4% to 13 million. Ischemic heart disease is also expected to rise by 30.7% to 29 million, and heart attacks by 16.9% to 16 million. Consequently, the growing cardiovascular disease incidence is propelling the calcium channel blocker market’s growth.

What Is The Overview Of Market Segmentation In The Calcium Channel Blocker Industry?

The calcium channel blocker market covered in this report is segmented –

1) By Drug Class: Dihydropyridine, Benzothiazepine, Phenylalkylamine, Other Drug Classes

2) By Disease Indications: Hypertension, Chest Pain, Arrhythmias

3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Dihydropyridine: Amlodipine, Nifedipine, Felodipine, Nicardipine, Isradipine

2) By Benzodiazepine: Diazepam

3) By Phenylalkylamine: Verapamil

4) By Other Drug Classes: Bepridil, Lercanidipine, Cilnidipine

Which Emerging Trends And Strategic Shifts Are Shaping The Calcium Channel Blocker Market?

The calcium channel blocker market is witnessing a surge in product innovation as a crucial trend. Major corporations in this market are emphasising on devising innovative products to preserve their prominence in the market. Take for example, CMP Pharma, a pharmaceutical production company situated in the US, released Norliqva in June 2022. This is the first and only oral liquid solution of the besylate salt of amlodipine, a long-lasting calcium channel blocker. The distinguishing aspect of Norliqva is its amlodipine liquid formulation which can be used to manage hypertension in people aged 6 years and older. Norliqva eliminates the complications and inconsistencies associated with crushing or creating amlodipine tablets, assuring a stable dosage and bioequivalence. It is particularly designed for a certain group of patients who need amlodipine but have difficulty swallowing or are incapable of swallowing.

Who Are The Primary Players Operating Across The Global Calcium Channel Blocker Market?

Major companies operating in the calcium channel blocker market include Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bausch Health Companies Inc., Lupin Pharmaceuticals Inc., Cadila Healthcare Limited, Covis Pharma BV, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Sofgen Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Knoll Healthcare Private Limited, Sanofi S.A., Clearsynth Labs Ltd., Searle LLC, Bayer AG, AstraZeneca plc, Wyeth-Ayerst Lederle Inc., GlaxoSmithKline Plc., AbbVie Inc., Silvergate Pharmaceuticals Inc., Exela Pharma Sciences LLC, Arbor Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/calcium-channel-blocker-global-market-report

Which Region Offers The Most Growth Potential For The Calcium Channel Blocker Market Through 2029?

North America was the largest region in the calcium channel blocker market in 2024. The regions covered in the calcium channel blocker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9428&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model